Newborn hemoglobin disorders
screening
The perfect match for screening hemoglobin disorders in newborns.
About Newborn Hemoglobin Disorders Screening
Every day more than one hundred thousand newborns are screened worldwide for metabolic and endocrine disorders. Although screening for hemoglobin has a long history in some countries (USA or UK), in other countries it is a recent addition to their screening panels (Portugal; Germany).
The increase of hemoglobin disorders in regions that previously did not see them has raised awareness of the importance of screening for them in newborns.
Early screening has proven to be effective in improving the lives of babies by providing appropriate treatment and follow-up.
Key benefits
Ease of use
All the steps are managed automatically by the instrument; it is easy to operate and requires few maintenance procedures.
Automatic result interpretation
Samples are automatically identified as normal or abnormal by the software, allowing laboratories to quickly detect and identify pathological results and quickly releasing non-pathological samples.
Excellent resolution
Thanks to Sebia Capillarys’ high resolution hemoglobins separation, the instrument allows the display of a clear profile, enabling easy identification of abnormal hemoglobin variants (S, C, D and E…) as well as abnormalities arising from thalassemia (Hb H, Hb Bart’s).
Early detection
Early detection of hemoglobin disorders allows appropriate treatment and follow up, improving the infant’s life while reassuring parents.
Main characteristics
The CAPI 3 NEONAT Hb kit is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobin (S, C, D, E and Bart’s) in blood from newborns collected on filter paper. This qualitative analysis is performed by capillary electrophoresis with the CAPILLARYS 3 DBS automated instrument.
Dried neonatal blood spots – Samples are punched (at 3.2 mm size), eluted in distilled water and analysed directly on the CAPILLARYS 3 DBS instrument.
Throughput (tests/hour)*
CAPI 3 NEONAT Hb
CAPILLARYS 3 DBS 70
* Using PHORESIS Software version 9.40 D
Dedicated reagent kit, Hemolysing solution and Hb AF control.
Reagents
- CAPI 3 NEONAT Hb – P/N: 2506
- CAPI 3 NEONAT Hemolysing solution – P/N: 2563
Controls
- CAPI 3 NEONAT Hb AF Control – P/N: 4757
- Hb AFSC Control* – P/N: 4792
* (optional pathological control)
Consumables
- CAPILLARYS 3 DBS Microplates – P/N: 2578
(10 units – 96 well barcoded microplates)
Featured instruments for Newborn hemoglobin Disorders Screening
See all instrumentsCAPILLARYS 3 DBS
The high throughput solution for newborn hemoglobin disorders screening.
Related resources
See all resourcesApr. 11, 2022 Dec. 21, 2024
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
CAPILLARYS 3 DBS – Introductory video
The perfect match for screening hemoglobin disorders in newborns
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
May. 22, 2023 May. 24, 2023
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices
The next generation instrument for screening hemoglobin disorders in newborns.
Scientific publications
See all publicationsNewborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019
This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.
Interested in Hemoglobin disorders screening?
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.